Analysts Maintain Positive Outlook on Autolus Despite Stock Volatility Autolus Therapeutics shares have shown significant short-term gains, rising over 11% on April 22 and up 22% in the past two weeks. Despite high volatility and a falling long-term trend, analysts maintain a consensus "Buy" rating, with price targets averaging $9.32, far above the current $1.60 level.1234